A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs EB-01 (Primary)
- Indications Allergic contact dermatitis
- Focus Therapeutic Use
- Sponsors Edesa Biotech
- 21 Oct 2019 According to an Edesa Biotech media release, the first patient has been enrolled in this trial. Edesa plans to perform a blinded interim analysis following the completion of the first cohort to determine the total number of patients for the second part of the study. Investigational centers for the EB01 study are located in Baton Rouge, LA; Bexley, OH; Chapel Hill, NC; Fridley, MN; Long Beach, CA; Louisville, KY; New York, NY; Plainfield, IN; and Washington, DC.
- 21 Oct 2019 Status changed from not yet recruiting to recruiting, as reported in an Edesa Biotech media release
- 14 Aug 2019 According to a Edesa Biotech media release, the company is performing site initiation visits at the investigational centers in the U.S. and expects to proceed with enrolling the first patient in this quarter.